Table 4 PECa (ng L− 1), PECb (ng L− 1), and risk categorization of the priority anticancer drug and their corresponding equivalents between the years 2013 and 2018
Active ingredient | Factor | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|---|---|
Azathioprine | PECa | 46.9 | 29.6 | 27.3 | 13.0 | 26.9 | 51.1 |
PECb | 23.4 | 14.8 | 13.6 | 6.5 | 13.4 | 25.5 | |
Class | IIA | IIA | IIA | III | IIA | IIA | |
Capecitibine | PECa | 98.9 | 74.1 | 83.7 | 83.1 | 83.1 | 54.3 |
PECb | 49.9 | 37.0 | 41.8 | 41.5 | 41.5 | 27.1 | |
Class | IIA | IIA | IIA | IIA | IIA | IIA | |
5- fluorocuracil | PECa | 1.4 | NA | NA | NA | 1.9 | 7.9 |
PECb | 0.7 | NA | NA | NA | 0.9 | 3.9 | |
Class | IV | NA | NA | NA | IV | IV | |
Mycophenolic acid | PECa | 12.1 | 41.3 | 62.0 | 56.6 | 38.4 | 43.4 |
PECb | 6.1 | 20.6 | 31.0 | 28.3 | 19.2 | 21.7 | |
Class | III | IIA | IIA | IIA | IIA | IIA | |
Mycophenolate mofetil | PECa | 218.0 | 212.4 | 167.7 | 233.4 | 161.2 | 185.9 |
PECb | 109.0 | 106.2 | 83.8 | 116.7 | 80.6 | 92.9 | |
Class | IA | IA | IIA | IA | IIA | IIA | |
Hydroxycarbamide | PECa | 64.7 | 117.9 | 73.1 | 54.8 | 77.1 | 115.2 |
PECb | 32.3 | 58.9 | 36.5 | 27.4 | 38.5 | 57.6 | |
Class | IIA | IIA | IIA | IIA | IIA | IIA | |
Mycophenolic acid equivalent | PECa | 169.1 | 194.2 | 182.8 | 224.7 | 154.4 | 177.2 |
PECb | 84.5 | 97.1 | 91.4 | 112.3 | 77.2 | 88.6 | |
Class | IIA | IIA | IIA | IA | IIA | IIA | |
5-fluorouracil equivalent | PECa | 37.3 | 26.8 | 30.3 | 30.1 | 32.0 | 27.6 |
PECb | 18.6 | 13.4 | 15.1 | 15.0 | 16.0 | 13.8 | |
Class | IIA | IIA | IIA | IIA | IIA | IIA |